Overcoming mTOR Resistance in Renal Cell Carcinoma
Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).
Clinical Pearls
Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).
- This study represents the first step in a long process: testing the hypothesis that HDAC inhibition can overcome resistance to mTOR inhibition
- Two patients treated with prior mTOR inhibitors progressed and then did well when treated with the combination of ridaforolimus and vorinostat
- Ridaforolimus 20 mg once daily plus vorinostat 100 mg once daily will be tested in a larger trial in patients who had both prior mTOR inhibitors and those who did not
<<<
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
